Biologics for Crohn's Go Head to Head
(MedPage Today) -- Ustekinumab (Stelara) or adalimumab (Humira) were similarly effective as induction or maintenance therapy for moderate to severe Crohn's disease, according to the randomized SEAVUE trial.
In an intention-to-treat analysis involving... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - June 14, 2022 Category: Gastroenterology Source Type: news
Could an Available Drug Stop Dupuytren's in Its Tracks?
(MedPage Today) -- A drug already on the market for 20 years effectively reduced nodules associated with Dupuytren's disease in a mid-stage trial, researchers said.
Patients receiving intranodular injections of adalimumab (Humira) showed significant... (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - May 3, 2022 Category: Primary Care Source Type: news
New Data Show Majority of Adults with Moderate to Severe Plaque Psoriasis Treated with First-in-Class TREMFYA ® (guselkumab) Experienced Durable Skin Clearance Through Five Years Regardless of Metabolic Syndrome Status, Baseline Disease Severity, or Treatment History
SPRING HOUSE, PENNSYLVANIA, March 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced its first-in-class interleukin (IL)-23 inhibitor TREMFYA® (guselkumab) provided a consistent, high degree of durable skin clearance through five years in a majority of adult patients across broad subpopulations with moderate to severe plaque psoriasis (PsO) in the Phase 3 VOYAGE 1 and VOYAGE 2 clinical trials.1 A separate post hoc analysis of the VOYAGE studies showed TREMFYA provided high rates of efficacy and durability through five years and similar safety outcomes among patients with and without...
Source: Johnson and Johnson - March 25, 2022 Category: Pharmaceuticals Source Type: news
Trial Gives New Guidance for Choosing Initial PsA Treatment Trial Gives New Guidance for Choosing Initial PsA Treatment
Adding the tumor necrosis factor inhibitor adalimumab to methotrexate because of a lack of efficacy or tolerability produced better results than escalating the methotrexate dose alone.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - March 21, 2022 Category: Internal Medicine Tags: Rheumatology News Source Type: news
Higher Adalimumab Dosing Regimens May Have Benefit in Ulcerative Colitis Higher Adalimumab Dosing Regimens May Have Benefit in Ulcerative Colitis
A higher-than-standard maintenance (but not induction) dosing regimen of adalimumab may be beneficial for some patients with moderate to severe ulcerative colitis, according to results of the SERENE UC study.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - March 11, 2022 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
AbbVie settles Humira lawsuit with Icelandic company Alvotech
The suit involved a biosimilar — that is, generic — version of the arthritis drug, which generated more than $20 billion in sales worldwide last year. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 9, 2022 Category: Pharmaceuticals Authors: Ben Miller Source Type: news
Endoscopic Healing of Crohn's Disease Could Differ by Biologic Endoscopic Healing of Crohn's Disease Could Differ by Biologic
Infliximab biosimilar and adalimumab resulted in better endoscopic healing rates than either vedolizumab or ustekinumab in a post hoc pooled analysis.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - March 3, 2022 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Remdesivir Takes Top Spot for US Hospital Spending: Report Remdesivir Takes Top Spot for US Hospital Spending: Report
The COVID-19 drug remdesivir last year overtook AbbVie ' s 20-year-old arthritis drug Humira as the medicine that US hospitals spent the most on.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 2, 2022 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news
Secukinumab vs. Adalimumab in Psoriatic Arthritis and Psoriasis Secukinumab vs. Adalimumab in Psoriatic Arthritis and Psoriasis
The results of this study provide evidence that the IL-17 inhibitor secukinumab is effective in managing the concomitant features of psoriasis and psoriatic arthritis.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 4, 2022 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news
FDA Approves Yusimry (adalimumab-aqvh), a Biosimilar to Humira
REDWOOD CITY, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:“CHRS”,“the Company”,“Coherus”) announced that the United States Food and Drug Administration (“FDA”)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 20, 2021 Category: Drugs & Pharmacology Source Type: news
Latest Phase 3 Data for First-in-Class TREMFYA ® (guselkumab) Demonstrates Significant and Durable Improvement in Signs and Symptoms of Active Psoriatic Arthritis while Maintaining its Safety Profile in Patients with Inadequate Response to Tumor Necrosis Factor Inhibition (TNFi-IR)
SPRING HOUSE, PENNSYLVANIA, December 3, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new TREMFYA® (guselkumab) efficacy and safety data from the Phase 3b COSMOS trial published in Annals of the Rheumatic Diseases (ARD), evaluating this selective interleukin (IL)-23 inhibitor in adults with active psoriatic arthritis (PsA) who demonstrated inadequate efficacy or intolerance to tumor necrosis factor inhibition (TNFi).1 Results showed significantly higher proportions of patients treated with TREMFYA had improvement in joint signs and symptoms and complete skin clearance versus placeb...
Source: Johnson and Johnson - December 3, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Suicidal and self-injurious behaviour following Adalimumab reference-to-generic biosimilar switch - Ward C, Farag M, Pollak TA, Coutinho E, Posporelis S.
[The publisher has not provided an abstract for this article.]
Language: en... (Source: SafetyLit)
Source: SafetyLit - November 22, 2021 Category: International Medicine & Public Health Tags: Suicide and Self-Harm Source Type: news
Colitis Study: Ozanimod Tops Adalimumab, Equals Vedolizumab Colitis Study: Ozanimod Tops Adalimumab, Equals Vedolizumab
In a statistical comparison, ozanimod matched vedolizumab and beat adalimumab for ulcerative colitis.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - November 2, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Drug maker AbbVie reports 'excellent' third quarter
Thanks to increased sales of its Humira, Skyrizi and Rinvoq immunology drugs, AbbVie Inc. reported a big increase in its third-quarter sales and earnings.
The North Chicago-based drug maker (Nasdaq: ABBV) reported third-quarter net revenue rose 11.2% to $14.342 billion, and adjusted diluted earnings per share rose 17.7% to $3.33, which were both above analysts' expectations. Analysts polled by Thomson Reuters First Call expected third-quarter revenu e of $14.3 billion and earnings of $3.22 per share.
""We… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - October 29, 2021 Category: American Health Authors: Ben Miller Source Type: news
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
